MedTrace Logo

Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality

NCT04141306 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-10-28

No results posted yet for this study

Summary

Bone radioiodine (RAI) uptake without structural abnormality in thyroid cancer (TC) patients may be related to false positive or to microscopic foci of metastatic tissue. In such cases, outcome is reported to be excellent.

Indeed, Robenshtok et al. reported a serie of patients with RAI-avid bone metastases of TC without structural abnormality on imaging studies who have more favorable long-term prognosis than those harbouring structurally visible bone metastases and do not undergo skeletal-related complications.

The investigators report the case of Mrs D., who had been operated for a pathologic tumor stage 3: pT3(m) poorly differentiated TC at the age of 43. The first post-therapeutic whole body scan revealed 3 foci of bone uptake (right clavicle, L2, L3). The elevated level of thyroglobulin (157ng/mL) favoured the hypothesis of bone metastases despite the absence of any structural lesion on CT and MRI. She received 7 courses of radioiodine therapy. The right clavicle RAI uptake persisted, and subsequent CT disclosed an osteolytic lesion which was treated by radiofrequency and external beam radiation. Twenty-five years after the diagnosis, she has a persistent morphological disease with a 30x8mm progressive lesion on the right clavicle, for which surgery is planned.

The aim of the present study is to describe the natural history and evolution of radioiodine avid bone metastases from thyroid cancer without structural abnormalities and to identify prognosis factors.

Conditions

Interventions

OTHER

Administrative data

Evaluation of month and year of birth, sex, referent doctor and surgeon

OTHER

Clinical data

Evaluation of diagnostic circumstances, vital status at last follow up

OTHER

Histological data

Evaluation of Pathology report of thyroid surgery

OTHER

Imaging data

Evaluation of scintigraphy, MRI, scan

OTHER

Biological data

Evaluation of thyroglobulin, antithyroglobulin antibodies

OTHER

Further treatment

Evaluation of surgery, radiotherapy, targeted therapy

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2019-12-31
Completion
2019-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141306 on ClinicalTrials.gov